TuisNVAX • SWX
add
Novavax Inc
Markkapitalisasie
1,65 mjd USD
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 147,14 m | 66,61% |
Bedryfskoste | 339,66 m | 260,54% |
Netto inkomste | 17,53 m | 121,63% |
Netto winsgrens | 11,91 | 112,98% |
Wins per aandeel | 0,11 | 121,33% |
EBITDA | 13,46 m | 111,92% |
Effektiewe belastingkoers | 2,10% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 735,08 m | -20,37% |
Totale bates | 1,18 mjd | -24,60% |
Totale aanspreeklikheid | 1,30 mjd | -40,29% |
Totale ekwiteit | -127,75 m | — |
Uitstaande aandele | 162,94 m | — |
Prys om te bespreek | — | — |
Opbrengs op bates | 1,77% | — |
Opbrengs op kapitaal | 19,34% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 17,53 m | 121,63% |
Kontant van bedrywe | -39,48 m | 77,20% |
Kontant van beleggings | 20,48 m | -85,78% |
Kontant van finansiering | -6,60 m | -92,99% |
Netto kontantverandering | -27,30 m | 36,93% |
Beskikbare kontantvloei | -36,36 m | 66,37% |
Meer oor
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
Gestig
1987
Webwerf
Werknemers
952
